Revenue segments as reported by the company.

Product revenue

Service and other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Goodwill Impairment

Restructuring costs

Intangible assets and other long-lived assets impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Bionano Genomics

Bionano Genomics, Inc. is a life sciences instrumentation company, which focuses on the genome analysis space. The firm engages in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline cytogenetics. Its products include Saphyr, Bionano Chips, Bionano Prep Kits, and Bionano Data Solutions. The company was founded by Han Cao in January 2003 and is headquartered in San Diego, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Bionano Genomics reports robust Q1 performance and strategic growth plans

Bionano Genomics demonstrated strong revenue growth and operational progress in Q1 2024.
While facing short-term revenue challenges, the company's strategic initiatives and product advancements position it for long-term success.
Efforts to reduce expenses and expand the customer base underscore Bionano's commitment to sustainable growth.

Bionano Genomics reports Q2 revenue decline, focuses on growth strategies

Bionano Genomics faced revenue decline in Q2 2024, attributed to discontinued services and challenges in China.
Despite operational streamlining efforts, the company aims to drive growth through product advancements and partnerships.
Lowered revenue guidance underscores the need for strategic adjustments to navigate market challenges and optimize performance.

Bionano Genomics reports Q3 revenue decline but shows cost efficiency

Bionano Genomics showcased operational improvements with cost reductions and growth in key metrics despite a revenue decline.
The company's focus on expense reduction, revenue growth, and profitability sets a strategic direction for future success.
Challenges persist in revenue generation and cost management, but opportunities in technology adoption and market expansion are evident.
Overall, Bionano Genomics aims to balance financial stability with growth initiatives to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNano may cause great disruption in the field of genetics. However, the payoff for investing in BNGO stock is likely to be years away.

BioNano Genomics Is About the Future, Not the Present

Investors in BNGO stock have seen year-over-year stock price appreciation of more than 2,200%, but can it continue long-term? The post Valuation Not Meme Stock Status Should Worry You About Bionano Genomics  appeared first on InvestorPlace.

Valuation Not Meme Stock Status Should Worry You About Bionano Genomics

Bionano Genomics, Inc. offers exposure to exciting high-growth themes like genomics and personalized medicine. BNGO offers a competitive product in the cytogenetics space that greatly reduces the inherent time and capital costs of genomics research.

Bionano Genomics: Recent Pullback A Strong Buy Opportunity

Zynerba Pharmaceuticals

While it doesn't get a lot of press, the Autism market is unfortunately a rapidly growing market opportunity. According to recent data from the CDC, roughly 2% of all kids are now diagnosed with Autism Spectrum Disorder (ASD).

Investing in Rapidly Growing Autism Therapy Market (NASDAQ: BNGO) (OTC US: ISWH) (NASDAQ: ZYNE)

Those investors bullish on genomics might want to analyze the Q4 results of BNGO stock The post BioNano Genomics Will Likely Be Volatile Prior to Q4 Earnings appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG It doesn't matter if you have $500 in savings or $5 million.

BioNano Genomics Will Likely Be Volatile Prior to Q4 Earnings

Technically, BNGO stock appeared on the verge of a robust breakout move but with shares tumbling instead, it's time to reassess the overall picture. The post BioNano Genomics Is an Excellent Lesson in Technical Analysis appeared first on InvestorPlace.

BioNano Genomics Is an Excellent Lesson in Technical Analysis

SAN DIEGO, March 15, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the following investor conferences:

Bionano Genomics to Present at Several Upcoming Investor Conferences

Bionano's Saphyr system looks poised to revolutionize diagnostics and medical research, making BNGO stock worth buying for long-term investors. The post Addressable Market Aside, Bionano Stock Is a Buy on Innovation Alone appeared first on InvestorPlace.

Addressable Market Aside, Bionano Stock Is a Buy on Innovation Alone

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management presented virtually at the H.C. Wainwright Global Life Sciences Conference, which took place March 9-10, 2021. The presentation by Bionano CEO Dr. Erik Holmlin is available on-demand through the H.C. Wainwright conference portal and the Events page in the Investors section of Bionano's website at https://ir.bionanogenomics.com/. It will be archived on Bionano's website for 30 days following the event.

Bionano Genomics Presented at H.C. Wainwright Global Life Sciences Conference

Bionano Genomics has a massive valuation based on recent capital raises. BNGO stock is fully valued at 108 times forward 2021 sales, even though sales may spike going forward.

Bionano Genomics Has the Cash to Push for Greatness

SAN DIEGO, March 09, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 23rd, 2021 at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2020 and to highlight recent corporate progress.

Bionano Genomics to Report Fourth Quarter and Year End 2020 Financial Results and Host a Conference Call and Webcast on March 23rd, 2021

Bionano Genomics (BNGO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why Bionano Genomics (BNGO) Might Surprise This Earnings Season

BNGO stock is on the high side right now, especially since it will likely take time for the company's system to get traction. The post Lofty Expectations Are Already Priced Into Bionano Genomics appeared first on InvestorPlace.

Lofty Expectations Are Already Priced Into Bionano Genomics

SAN DIEGO, March 03, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that Praxis Genomics, LLC received DEX Z-codes from Palmetto MolDX for its entire testing menu of laboratory developed tests (LDTs) based on Saphyr. The DEX Z-Code modifier is a unique 5-character alpha-numeric code associated with certain molecular diagnostics tests and is typically used by certain payers as an adjunct to non-specific CPT codes when no specific CPT code applies. The code, submitted on a claim along with a particular CPT code provides greater clarity to help payers and physicians understand which test is being ordered, performed and billed. The process removes the need for the provider to submit large amounts of additional information with every claim and can expedite claim payment. The assignment of DEX Z-codes to Praxis's menu of Saphyr-based LDTs is potentially a major step forward in the coding and eventual coverage of Saphyr-based tests.

Bionano Customer Praxis Genomics Receives DEX Z-Codes from Palmetto for their Whole Genome Analysis LDT on Saphyr

Bionano Genomics Inc Units Cons of 1 Sh + 1 Wt 20.08.23

BNGO stock shot up massively in the past few months. Now isn't the time to invest as the company must first prove its technology sells.

Bionano Genomics Would Have Been a Great Find Months Ago

SAN DIEGO, March 02, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management will present virtually at the Cowen 41st Annual Health Care Conference. Erik Holmlin, PhD, Bionano's Chief Executive Officer, is scheduled to present on Thursday, March 4, 2021 at 2:10 pm EST.

Bionano Genomics to Present at the Cowen 41st Annual Health Care Conference

Bionano Genomics, Inc. (BNGO) closed at $9.84 in the latest trading session, marking a +1.13% move from the prior day.

Bionano Genomics, Inc. (BNGO) Gains But Lags Market: What You Should Know

Without revenue growth, it's hard to be bullish on BNGO stock for the long-term The post It's Time to Take Profits on Volatile BioNano Genomics Stock and Buy It Back on Dips appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next Potential Winner It doesn't matter if you have $500 in savings or $5 million.

It's Time to Take Profits on Volatile BioNano Genomics Stock and Buy It Back on Dips

SAN DIEGO, March 01, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that the 2021 Advances in Genome Biology and Technology (AGBT) meeting will feature presentations from scientists at leading research institutes and hospitals including Boston Children's Hospital, Harvard Medical School, Tel Aviv University and the company describing their work with the Saphyr System for optical genome mapping (OGM) in psychiatric disorders and cancer. AGBT will be held virtually at https://www.agbt.org/ March 1-3. Bionano's optical genome mapping technology will be discussed in poster presentations and plenary talks on AGBT's main agenda. Additionally, Bionano will host a live interview with Bionano CEO Dr. Erik Holmlin and CMO Dr. Alka Chaubey conducted by Theral Timpson, Host, Producer and Co-Founder of Mendelspod as part of the official conference program. The recording of the interview will be released on Thursday, March 4 as a regular episode of Mendelspod, the leading podcast covering the genomics industry.

Bionano to be Featured at AGBT 2021 with Presentations of Scientific Discoveries made with Saphyr in Psychiatric Disorders and Cancer

Article published in Science reveals that optical genome mapping uniquely makes thousands of large structural variant calls Article published in Science reveals that optical genome mapping uniquely makes thousands of large structural variant calls

Bionano's Saphyr Data Prove Essential in Creating the Most Comprehensive, Ethnically Diverse Collection of Genome Variation Ever Completed

BioNano Genomics shares have been big movers, gaining nearly 3,000% over the past three months, then crashing hard on Tuesday. The post BioNano Genomics Stock Is Crashing For a Reason appeared first on InvestorPlace.

BioNano Genomics Stock Is Crashing For a Reason

BNGO Stock has alot of potential for growth in the long term but its risks currently limit its attractiveness as an investment The post Investors Should Have BNGO Stock on Their Long-Term Watch List appeared first on InvestorPlace. More From InvestorPlace Why Everyone Is Investing in 5G All WRONG Top Stock Picker Reveals His Next Potential Winner It doesn't matter if you have $500 in savings or $5 million.

Investors Should Have BNGO Stock on Their Long-Term Watch List

BNGO stock is on the move today without any real company news. Here's what you should know about Bionano Genomics now.

BNGO Stock: What to Know as Bionano Genomics Drops 15% Today

Nano Dimension

Let's take a look at two companies that Wood has her eye on and has recently added to Ark's large portfolio of funds.

2 Stocks that Ark Invest loves for 2021

BNGO stock is an investment in the future of gene discovery and therapy as Bionano pushes the boundaries of optical genome mapping tech. The post Leverage the Power of Genetics Tech With Bionano Genomics appeared first on InvestorPlace.

News for Bionano Genomics Stock (BNGO)